A Phase II/III Adaptive Seamless Design, Randomized, Controlled Trial To Evaluate Safety And Immunogenicity of 2 Dose-Regimen of BBV87 Chikungunya Vaccine In Healthy Subjects Aged 12 to 65 Years in Latin America and Asia.
Latest Information Update: 27 Jun 2025
At a glance
- Drugs Chikungunya virus vaccine (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms IVICHIK001
Most Recent Events
- 22 Jun 2025 Status changed from active, no longer recruiting to discontinued.
- 16 Apr 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 16 Apr 2023 Status changed from recruiting to active, no longer recruiting.